GHRP-2 and GHRP-6 Compared

For laboratory research use only. Not for human or veterinary use.

GHRP-2 and GHRP-6 are asked about together more than almost any other pair of research peptides, and most of what is written about them online compares vague impressions rather than the two molecules. This guide sets out what each one actually is — sequence, formula, mass, receptor — where the structural difference lies, and what that difference does and does not mean.

What they have in common#

Both are synthetic hexapeptides: six amino acids, chemically manufactured rather than extracted. Both belong to the class known as growth hormone secretagogues, and both act as agonists at the growth hormone secretagogue receptor (GHS-R), now more commonly called the ghrelin receptor.

Both descend from the same line of work. They were developed from synthetic analogues of met-enkephalin, an endogenous opioid peptide, in a research programme that ran through the 1980s. The finding that drove the field was that certain enkephalin-derived structures stimulated growth hormone release through a receptor entirely separate from the one growth hormone-releasing hormone uses — a second, independent pathway. The receptor those compounds were binding was identified before its natural ligand was. Ghrelin, the endogenous molecule that occupies it, was not characterised until 1999.

That history is why both compounds are sometimes described as ghrelin mimetics: they were found first and explained afterwards.

Side by side#

The two molar masses are 55 g/mol apart. That matters practically: a mass spectrum is the quickest way to tell which compound is actually in the vial, and the two are far enough apart that there is no ambiguity.

Where the structures diverge#

Look at positions one and two. Everything from position three onward — Ala-Trp-D-Phe-Lys-NH₂ — is identical.

• GHRP-6 opens with histidine, then D-tryptophan.
• GHRP-2 opens with D-alanine, then D-2-naphthylalanine.

D-2-Nal is not one of the twenty amino acids biology uses. It is a synthetic residue carrying a naphthalene ring — two fused aromatic rings in place of tryptophan's single indole. Substituting it does two things at once: it enlarges the hydrophobic contact the molecule makes with the receptor pocket, and because no endogenous protease is evolved to cut next to a non-natural residue, it slows enzymatic breakdown.

That single substitution is most of the difference between the two compounds. GHRP-2 is the more potent of the pair at the receptor, milligram for milligram, and this is the structural reason why.

The appetite difference#

The other commonly cited distinction is appetite. GHRP-6 is widely described as the stronger of the two here, but we have not found a published study comparing them directly. The one controlled human study of GHRP-2 we know of found it raised food intake by about 36% in seven healthy men (see Sources).

This is not a side effect in the pharmacological sense — it is the ghrelin pathway doing exactly what it does. Ghrelin is the body's own hunger signal, and any compound occupying its receptor engages that signalling alongside growth hormone release. The two effects share a receptor; separating them is a matter of degree, not of mechanism.

For research design, this is the practical consequence: the two compounds are not interchangeable controls for each other. If the pathway under study intersects with appetite regulation, the choice between them changes what you are measuring.

Why “which is better” is usually the wrong question#

Most comparisons of these two compounds are framed as a ranking. That framing does not survive contact with the pharmacology, because they are the same mechanism at different potencies with different secondary weighting on a shared pathway. Neither is a stronger version of the other; they occupy different positions on the same axis.

The useful questions are narrower. Which receptor interactions does the study need to isolate? Does appetite signalling confound the measurement or form part of it? Is potency per milligram a variable that matters here, or is molar equivalence being controlled for anyway? Those have answers. “Which is better” does not.

What to check on the certificate#

Both compounds are manufactured by solid-phase synthesis and both are supplied as a lyophilised powder, which means the certificate matters more than the label. Four things are worth reading on any batch document for either compound.

• Mass spectrometry. The observed mass should correspond to the monoisotopic mass, which is not the molar mass in the table above — a spectrometer measures a single isotopic species, while the molar mass is averaged across the natural isotope distribution. For GHRP-2 the two are 817.43 and 817.99. This is the identity check, and it is the one that distinguishes GHRP-2 from GHRP-6 unambiguously.
• HPLC purity. Reported as measured on that batch, with the method named. A figure with no method behind it is a number, not a result.
• Net peptide content. Distinct from purity, and routinely conflated with it. A lyophilised peptide carries counter-ions and residual water; net peptide content is how much of the vial mass is peptide. A batch can be highly pure and still be substantially salt.
• Counter-ion. Usually acetate or trifluoroacetate, from the purification step. Which one it is affects the net peptide figure and, for some assays, the result.

Ask about the documentation for the batch we would ship before you order. Our guides on how to read a COA and what a purity figure actually means go through each of these in detail.

Handling and storage#

Both compounds behave the same way in storage, which simplifies matters if you hold both.

As a lyophilised powder, sealed and kept cold and dark, either is stable for a long period — this is the reason peptides are freeze-dried in the first place. Once in solution, that changes: stability drops sharply, and the material becomes sensitive to temperature, light, repeated freeze-thaw cycles and time. The storage guide covers the conditions in detail, and the reconstitution guide covers returning the powder to solution without degrading it.

Both are tryptophan-containing peptides, which makes light protection more than a formality — tryptophan is among the more photosensitive residues, and an amber vial or foil wrap is a reasonable default for either.

What Pioneer supplies#

GHRP-2 and GHRP-6 are both stocked as 5mg lyophilised vials at the same price. They ship from the UK with same-day dispatch on orders before 2pm, alongside the bacteriostatic or sterile water and transfer equipment to work with them.

Quality comes first#

Comparing two compounds is only meaningful if each vial contains what its label says. Ask about the documentation for the batch we would ship before you order.

Sources#

Status elsewhere: In Japan, a GHRP-2 test is one of the recommended clinical tests of pituitary growth hormone release.

Each entry links to its PubMed record, where the title and abstract can be read. The descriptions are ours: they say what each paper examined, not what it is claimed to show. Records checked on PubMed on 28 October 2026.

1. Bowers CY, Momany FA, Reynolds GA, et al. (1984). Endocrinology 114(5):1537–45. The first report of GHRP-6 ([His1,Lys6]-GHRP): growth hormone release in pituitary preparations and in several animal species. PubMed 6714155
2. Howard AD, Feighner SD, Cully DF, et al. (1996). Science 273(5277):974–7. Cloning of the receptor these compounds act on, the growth hormone secretagogue receptor, now usually called the ghrelin receptor. PubMed 8688086
3. Kojima M, Hosoda H, Date Y, et al. (1999). Nature 402(6762):656–60. Identification of ghrelin, the receptor’s natural ligand, from the stomach. PubMed 10604470
4. Bowers CY (2012). Methods Enzymol 514:3–32. The originator’s own history of the field, from the first synthetic GHRPs in the 1970s to the discovery of ghrelin. PubMed 22975043
5. Laferrère B, Abraham C, Russell CD, et al. (2005). J Clin Endocrinol Metab 90(2):611–4. Small study in seven healthy men measuring food intake during a GHRP-2 infusion, compared with saline. PubMed 15699539
6. Chihara K, Shimatsu A, Hizuka N, et al. (2007). Eur J Endocrinol 157(1):19–27. Japanese multicentre study in 135 people validating a GHRP-2 test of pituitary growth hormone release. PubMed 17609397
7. Kinoshita Y, Tominaga A, Usui S, et al. (2013). Endocr J 60(1):97–105. Japanese comparison in 71 patients of the GHRP-2 test with the standard insulin tolerance test. Notes that the GHRP-2 test is one of the recommended alternatives in Japan. PubMed 23079545

In our catalogue#

• GHRP-2 — growth hormone releasing peptide 2, 10mg
• GHRP-6 — growth hormone releasing peptide 6, 10mg
• Ipamorelin — selective ghrelin receptor research
• CJC-1295 (without DAC) + Ipamorelin — combined GHRH and GHRP blend

Pioneer Research Peptides — UK supplier of research peptides for laboratory use. Ask about batch documentation before you order.

For laboratory research use only — not for human consumption. 18+.